DHAP in combination with rituximab vs DHAP alone as salvage treatment for patients with relapsed or refractory diffuse large B-cell lymphoma: a matched-pair analysis

References

• Fisher R I, Gaynor E R, Dahlberg S, Oken M M, Grogan T M, Mize E M, et al. A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate- or high-grade non-Hodgkin's lymphoma: results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma Study. Ann Oncol 1994; 5: 91–95
   PubMed Web of Science ®Google Scholar
• Fisher R I, Miller T P, O'Connor O A. Diffuse aggressive lymphoma. Hematology (Am Soc Hematol Educ Program) 2004; 221–236
   PubMedGoogle Scholar
• Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540–1545
   PubMed Web of Science ®Google Scholar
• Velasquez W S, McLaughlin P, Tucker S, Hagemeister F B, Swan F, Rodriguez M A, et al. ESHAP—an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol 1994; 12: 1169–1176
   PubMed Web of Science ®Google Scholar
• Wilson W H, Bryant G, Bates S, Fojo A, Wittes R E, Steinberg S M, et al. EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma. J Clin Oncol 1993; 11: 1573–1582
   PubMed Web of Science ®Google Scholar
• Rodriguez M A, Cabanillas F C, Velasquez W, Hagemeister F B, McLaughlin P, Swan F, Romaguera J E. Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP. J Clin Oncol 1995; 13: 1734–1741
   PubMed Web of Science ®Google Scholar
• Rodriguez J, Rodriguez M A, Fayad L, McLaughlin P, Swan F, Sarris A, et al. ASHAP: a regimen for cytoreduction of refractory or recurrent Hodgkin's disease. Blood 1999; 93: 3632–3636
   PubMed Web of Science ®Google Scholar
• Zhou S Y, Shi Y K, He X H, Zhang P, Dong M, Huang D Z, et al. [Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high grade non-Hodgkin's lymphoma]. Ai Zheng 2005; 24: 465–469
   PubMedGoogle Scholar
• Moskowitz C. Risk-adapted therapy for relapsed and refractory lymphoma using ICE chemotherapy. Cancer Chemother Pharmacol 2002; 49: S9–S12, Epub 12 Apr 2002
   PubMed Web of Science ®Google Scholar
• Moskowitz C H, Bertino J R, Glassman J R, Hedrick E E, Hunte S, Coady-Lyons N, et al. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J Clin Oncol 1999; 17: 3776–3785
   PubMed Web of Science ®Google Scholar
• Coiffier B. Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkin's lymphoma. Semin Oncol 2002; 29: 18–22
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Truemper L, Osterborg A, Pettengell R, Trneny M, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-pragnosis diffuse large-B-cell lymphoma; a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7: 379–391
   PubMed Web of Science ®Google Scholar
• Habermann T M, Weller E, Morrison V A, Cassileth P A, Cohn J, Dakhil S, et al. Rituximab-CHOP versus CHOP with or without maintenance rituximab in patients 60 years of age or older with diffuse large B-cell lymphoma (DLBCL): an update. Blood 2004; 104([abstract 127])
   PubMed Web of Science ®Google Scholar
• Kewalramani T, Zelenetz A D, Nimer S D, Portlock C, Straus D, Noy A, et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2004; 103: 3684–3688, Epub 22 Jan 2004
   PubMed Web of Science ®Google Scholar
• Jermann M, Jost L M, Taverna C, Jacky E, Honegger H P, Betticher D C, et al. Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study. Ann Oncol 2004; 15: 511–516
   PubMed Web of Science ®Google Scholar
• Younes A, Mclauglin P, Hagemeister F B, Pro B, Samaniego F, Romaguera J, et al. High response rate and complete remission rate achieved by adding rituximab to Taxol and topotecan (TTR) with G-CSF support for the treatment of patients with relapsed/ refractory aggressive B-cell lymphoma. Blood 2001; 98: 345a
   Web of Science ®Google Scholar
• Mey U JM, Orlopp K S, Flieger D, Strehl J W, Ho A D, Hensel M, et al. Dexamethasone, high-dose cytarabine, and cisplatin in combination with rituximab as salvage treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma. Cancer Invest 2006; 24: 593–600
   PubMed Web of Science ®Google Scholar
• Olivieri A, Brunori M, Capelli D, Montanari M, Massidda D, Gini G, et al. Salvage therapy with an outpatient DHAP schedule followed by PBSC transplantation in 79 lymphoma patients: an intention to mobilize and transplant analysis. Eur J Haematol 2004; 72: 10–17
   PubMed Web of Science ®Google Scholar
• Cheson B D, Horning S J, Coiffier B, Shipp M A, Fisher R I, Connors J M, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244
   PubMed Web of Science ®Google Scholar
• Velasquez W S, Cabanillas F, Salvador P, McLaughlin P, Fridrik M, Tucker S, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 1988; 71: 117–122
   PubMed Web of Science ®Google Scholar
• Martelli M, Cimino G, Gastaldi R, Mantovani L, Sgadari C, Amadori S, Guglielmi C. DHAP treatment: results of 18 patients with refractory or recurrent non Hodgkin's lymphoma. Haematologica 1990; 75: 194–195
   PubMed Web of Science ®Google Scholar
• Press O W, Livingston R, Mortimer J, Collins C, Appelbaum F. Treatment of relapsed non-Hodgkin's lymphomas with dexamethasone, high-dose cytarabine, and cisplatin before marrow transplantation. J Clin Oncol 1991; 9: 423–431
   PubMed Web of Science ®Google Scholar
• Philip T, Chauvin F, Bron D, Guglielmi C, Hagenbeek A, Coiffier B, et al. PARMA international protocol: pilot study on 50 patients and preliminary analysis of the ongoing randomized study (62 patients). Ann Oncol 1991; 2: 57–64
   PubMed Web of Science ®Google Scholar
• Olivieri A, Offidani M, Ciniero L, Cantori I, Ombrosi L, Mancini S, et al. DHAP regimen plus G-CSF as salvage therapy and priming for blood progenitor cell collection in patients with poor prognosis lymphoma. Bone Marrow Transplant 1995; 16: 85–93
   PubMed Web of Science ®Google Scholar
• Rodriguez-Monge E J, Cabanillas F. Long-term follow-up of platinum-based lymphoma salvage regimens. The M.D. Anderson Cancer Center experience. Hematol Oncol Clin North Am 1997; 11: 937–947
   PubMed Web of Science ®Google Scholar
• Li Y H, Jiang W Q, Huang H Q, Zhang L, Liu D G, Xu R H, et al. [Preliminary study on DHAP regimen for patients with relapsed and refractory non-Hodgkin's lymphoma]. Ai Zheng 2002; 21: 900–902
   PubMedGoogle Scholar
• Josting A, Sieniawski M, Glossmann J P, Staak O, Nogova L, Peters N, et al. High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study. Ann Oncol 2005; 6: 6
   Google Scholar
• Nuckel H, Durig J, Duhrsen U. Salvage chemotherapy according to the ASHAP protocol: a single-center study of 24 patients with relapsed or refractory aggressive non-Hodgkin's lymphomas. Ann Hematol 2003; 82: 481–486, Epub 21 Jun 2003
   PubMed Web of Science ®Google Scholar
• Child J A, Johnson S A, Rule S, Smith G M, Morgan G J, Johnson P W, et al. FLUDAP: salvage chemotherapy for relapsed/refractory aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 2000; 37: 309–317
   PubMed Web of Science ®Google Scholar
• Girouard C, Dufresne J, Imrie K, Stewart A K, Brandwein J, Prince H M, et al. Salvage chemotherapy with mini-BEAM for relapsed or refractory non-Hodgkin's lymphoma prior to autologous bone marrow transplantation. Ann Oncol 1997; 8: 675–680
   PubMed Web of Science ®Google Scholar
• Goss P E, Shepherd F A, Scott J G, Warner E, Baker M A, Sutton D, et al. Dexamethasone/ifosfamide/cisplatin/etoposide (DICE) as therapy for patients with advanced refractory non-Hodgkin's lymphoma: preliminary report of a phase II study. Ann Oncol 1991; 2: 43–46
   PubMed Web of Science ®Google Scholar
• Choi C W, Paek C W, Seo J H, Kim B S, Shin S W, Kim Y H, Kim J S. ESHAP salvage therapy for relapsed or refractory non-Hodgkin's lymphoma. J Korean Med Sci 2002; 17: 621–624
   PubMed Web of Science ®Google Scholar
• Wang W S, Chiou T J, Liu J H, Fan F S, Yen C C, Tung S L, Chen P M. ESHAP as salvage therapy for refractory non-Hodgkin's lymphoma: Taiwan experience. Jpn J Clin Oncol 1999; 29: 33–37
   PubMed Web of Science ®Google Scholar
• Emmanouilides C, Jazirehi A R, Bonavida B. Rituximab-mediated sensitization of B-non-Hodgkin's lymphoma (NHL) to cytotoxicity induced by paclitaxel, gemcitabine, and vinorelbine. Cancer Biother Radiopharm 2002; 17: 621–630
   PubMed Web of Science ®Google Scholar
• Alas S, Ng C P, Bonavida B. Rituximab modifies the cisplatin-mitochondrial signaling pathway, resulting in apoptosis in cisplatin-resistant non-Hodgkin's lymphoma. Clin Cancer Res 2002; 8: 836–845
   PubMed Web of Science ®Google Scholar
• Demidem A, Lam T, Alas S, Hariharan K, Hanna N, Bonavida B. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 1997; 12: 177–186
   PubMed Web of Science ®Google Scholar
• Wilson W H. Chemotherapy sensitization by rituximab: experimental and clinical evidence. Semin Oncol 2000; 27: 30–36
   PubMed Web of Science ®Google Scholar
• Gutierrez M, Chabner B A, Pearson D, Steinberg S M, Jaffe E S, Cheson B D, et al. Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH. J Clin Oncol 2000; 18: 3633–3642
   PubMed Web of Science ®Google Scholar
• Wilder D D, Ogden J L, Jain V K. A multicenter trial of infusional etoposide, doxorubicin, and vincristine with cyclophosphamide and prednisone (EPOCH) in patients with relapsed non-Hodgkin's lymphoma. Clin Lymphoma 2001; 1: 285–292
   PubMedGoogle Scholar
• Biagi J, Herbert K, Smith C, Abdi E, Leahy M, Falkson C, et al. A phase II study of dexamethasone, ifosfamide, cisplatin and etoposide (DICE) as salvage chemotherapy for patients with relapsed and refractory lymphoma. Leuk Lymphoma 2005; 46: 197–206
   PubMed Web of Science ®Google Scholar
• Leo E, Scheuer L, Schmidt-Wolf I G, Kerowgan M, Schmitt C, Leo A, et al. Significant thrombocytopenia associated with the addition of rituximab to a combination of fludarabine and cyclophosphamide in the treatment of relapsed follicular lymphoma. Eur J Haematol 2004; 73: 251–257
   PubMed Web of Science ®Google Scholar
• Hoerr A L, Gao F, Hidalgo J, Tiwari D, Blum K A, Mathews V, et al. Effects of pretransplantation treatment with rituximab on outcomes of autologous stem-cell transplantation for non-Hodgkin's lymphoma. J Clin Oncol 2004; 22: 4561–4566
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235–242
   PubMed Web of Science ®Google Scholar
• Vose J, Sneller V. Outpatient regimen rituximab plus ifosfamide, carboplatin and etoposide (R-ICE) for relapsed non-Hodgkin's lymphoma. Ann Oncol 2003; 14: i17–i20
   PubMed Web of Science ®Google Scholar
• Davis T A, Grillo-Lopez A J, White C A, McLaughlin P, Czuczman M S, Link B K, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 2000; 18: 3135–3143
   PubMed Web of Science ®Google Scholar
• Shimoni A, Hardan I, Avigdor A, Yeshurun M, Raanani P, Ben-Bassat I, Nagler A. Rituximab reduces relapse risk after allogeneic and autologous stem cell transplantation in patients with high-risk aggressive non-Hodgkin's lymphoma. Br J Haematol 2003; 122: 457–464
   PubMed Web of Science ®Google Scholar
• Khouri I F, Saliba R M, Hosing C, Okoroji G J, Acholonu S, Anderlini P, et al. Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas. J Clin Oncol 2005; 23: 2240–2247
   PubMed Web of Science ®Google Scholar